According to Bloomberg, Novartis AG is preparing for significant demand for its new gene therapy, a potential blockbuster targeting a disease that kills infants. Now the company is looking at the potential for installment payment plans for a treatment that could command a multimillion-dollar price.
Questions:
1. At what price does Novartis estimate that the drug Zolgensma could be cost-effective?
2. The treatment is a potential cure for what disease?
3. If Zolgensma is an alternative to Biogen Inc.’s drug Spinraza, what is the benefit of having two drugs for the same condition?
Source:
Paton, J. (2019). Novartis Sees High Demand for Possible Multimillion-Dollar Drug. Bloomberg, Jan. 31 (Retrievable online at https://www.bloomberg.com/news/articles/2019-01-30/novartis-prepares-for-significant-demand-for-new-gene-therapy)